Polaryx Therapeutics Secures Nasdaq Listing Ahead of Phase 2 Trial for Rare Lysosomal Storage Disorders
核心洞察
Polaryx Therapeutics (搜索) received approval for direct listing on Nasdaq under ticker symbol "PLYX" with trading expected to commence February 2, 2026.
The clinical-stage biotech is preparing to launch SOTERIA, a Phase 2 basket trial evaluating lead candidate PLX-200 across multiple lysosomal storage disorder indications.
PLX-200 holds three FDA orphan drug designations and targets approximately 33% of the lysosomal storage disease population, including neuronal ceroid lipofuscinoses (搜索), Krabbe disease (搜索), and Tay-Sachs and Sandhoff diseases.
Polaryx Therapeutics (搜索), a clinical-stage biotechnology company focused on rare pediatric lysosomal storage disorders (搜索), announced approval for direct listing on the Nasdaq Capital Market under the ticker symbol "PLYX," with trading expected to begin February 2, 2026. The milestone comes as the company prepares to launch its pivotal Phase 2 trial for lead candidate PLX-200.
Strategic Timing for Clinical Development
The Nasdaq listing coincides with Polaryx's plans to initiate SOTERIA, a single-arm, open-label Phase 2 trial designed to evaluate PLX-200's safety, tolerability, and clinical activity across multiple lysosomal storage disorder (LSD) indications. The basket trial design aims to address what the company describes as "tremendous unmet need" in this patient population.
"This direct listing on one of the world's leading stock market exchanges represents an important opportunity for Polaryx to reach a broad class of investors who share our dedication to delivering family-friendly therapies for pediatric patients fighting devastating rare orphan LSDs," said Alex Yang, Polaryx's Chairman and Chief Executive Officer.
Comprehensive Pipeline Targeting Rare Diseases
Polaryx is advancing four product candidates—PLX-200, PLX-300, PLX-100, and PLX-400 (搜索)—to address lysosomal storage disorders (搜索) affecting an estimated 50,000 patients across the US, Europe, and other locations. The lead candidate PLX-200 has secured three FDA orphan drug designations and is being developed through a 505(b)(2) regulatory pathway.
The planned multi-indication Phase 2 basket trial for PLX-200 is expected to cover approximately 33% of the lysosomal storage disease population, with target indications including neuronal ceroid lipofuscinoses (搜索), Krabbe disease (搜索), and Tay-Sachs and Sandhoff diseases.
Financial Structure and Market Positioning
The direct listing will allow existing shareholders to sell shares without the company raising new capital. In September 2025, Polaryx sold 1.9 million shares at $0.64 per share. If shares list at that reference price, the company would command a market capitalization of approximately $121 million.
Maxim Group LLC (搜索) served as exclusive financial advisor for the direct listing, while Gibson, Dunn & Crutcher LLP provided legal counsel and Brownstein Hyatt Farber Schreck, LLP served as Nevada counsel.
Enhanced Investor Communications
Concurrent with the listing announcement, Polaryx revealed plans to launch a dedicated Investor Relations section on its website at https://investors.polaryx.com/. The platform will serve as a central resource for stockholders, featuring stock information, press releases, stockholder meeting details, and frequently asked questions.
Founded in 2014 and based in Paramus, New Jersey, Polaryx represents a focused approach to addressing rare pediatric lysosomal storage disorders (搜索), a therapeutic area with significant unmet medical need and limited treatment options.